Current Treatment Landscape for Second and Subsequent Lines of Therapy in Metastatic Urothelial Carcinoma

Download this slideset to review the latest data on treatment for patients with progressive urothelial carcinoma along with insights on new horizons for immunotherapy in urothelial carcinoma.
Alain Ravaud, MD, PhD
Format: Microsoft PowerPoint (.ppt)
File Size: 1.76 MB
Released: September 21, 2020

Acknowledgements

Supported by an educational grant from
Pfizer, Inc. and EMD Serono

Related Content

Slides from Arjun Balar, MD on optimal selection of first-line treatment for patients with advanced urothelial cancer, from Clinical Care Options (CCO)

person default Arjun Balar, MD Released: May 6, 2021

Expert insight from Arjun Balar, MD, on choosing optimal first-line therapy for patients with advanced urothelial or bladder cancer, from Clinical Care Options (CCO)

person default Arjun Balar, MD person default Kaitlynn Francese, MSN, RN, OCN Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: May 6, 2021 Expired: May 5, 2022

Expert insight from Arjun Balar, MD, on choosing optimal therapy for patients with advanced urothelial cancer after chemo and IO, from Clinical Care Options (CCO)

person default Arjun Balar, MD person default Kaitlynn Francese, MSN, RN, OCN Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: May 4, 2021 Expired: May 3, 2022

Slides from Arjun Balar, MD on the role of antibody-drug conjugates in early stage urothelial cancer, from Clinical Care Options (CCO)

person default Arjun Balar, MD Released: May 4, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue